RAD51D | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

40 results for “RAD51D”

Trials

View all 27 →

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

65 participants · First posted Apr 22, 2022

Active, not recruiting

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

11 participants · First posted Sep 5, 2021

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

100 participants · First posted Jul 30, 2019

Drugs

RAD51 inhibitor (Satyarx)

RAD51 inhibitors(Cyteir Therapeutics)

RAD52 inhibitors (Satya Pharma)

News

Lynparza Shows Promise as Non-Hormonal Therapy for Prostate Cancer with HRR Mutations

Saruparib Shows Promise in HRR-Deficient Breast Cancer

Real-World Data Shows Olaparib Benefits mCRPC Patients with HRR Mutations

Page 1 of 4